Why Is HilleVax (HLVX) Stock Down 87% Today?

How This Affects HLVX Stock Read More:Penny Stocks — How to Profit Without Getting Scammed HilleVax (NASDAQ:HLVX) stock is falling hard on Monday following the release of topline data from its Phase 2b clinical trial of HIL-214 in infants. HilleVax CEO Rob Hershberg said the following about the news. Shares of HLVX stock are taking a beating alongside heavy trading today. This has more than 17 million shares traded as investors offload the stock on the failed clinical trial news. To put that number in persp ...